Press coverage about Immune Pharmaceuticals (NASDAQ:IMNP) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.1879253157906 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Immune Pharmaceuticals (NASDAQ IMNP) opened at 1.52 on Wednesday. The stock’s 50 day moving average price is $2.63 and its 200 day moving average price is $1.56. The company’s market capitalization is $15.33 million. Immune Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $5.02.

COPYRIGHT VIOLATION NOTICE: “Immune Pharmaceuticals (NASDAQ:IMNP) Receiving Somewhat Favorable News Coverage, Analysis Shows” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/09/immune-pharmaceuticals-nasdaqimnp-receiving-somewhat-favorable-news-coverage-analysis-shows.html.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

Insider Buying and Selling by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.